health TALAPRO-3 Shows PARP Inhibitor Combo Delays Prostate Cancer Progression
Phase 3 trial results presented at ASCO 2026 show talazoparib plus enzalutamide significantly improves radiographic progression-free survival in HRR-deficient metastatic castration-sensitive prostate cancer.
